about
Cost-effectiveness in the management of patients with oesophageal cancer.Cost-effectiveness of continuous erythropoietin receptor activator in anemia.A guide to undertaking economic evaluations within randomized controlled trials of treatments for lower urinary tract symptoms.Economic note: cost of illness studies.What does a GP consultation cost?Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable.The primary prevention of coronary heart disease with statins: practice headache or public health?Management of UTI in general practice: a cost effective analysis. A commentary to facilitate an understanding of economic evaluation.An introduction to economic evaluation of health care.Ultrasound in prenatal diagnosis: polemics around routine ultrasound screening for second trimester fetal malformations.Economics and preventing hospital-acquired infection.Introduction to health economics for the medical practitioner.An introduction to economic evaluationBeing economical with the truth: how to make your idea appear cost effective.Quantifying the healthcare costs of treating severely bleeding major trauma patients: a national study for England.An introduction to economic evaluation: what's in a name?An introduction to the basic principles of health economics for those involved in the development and delivery of headache care.Economic evaluations: a new avenue of outcome assessment in spinal disordersA Health Technology Assessment: laparoscopy versus colpoceliotomy.Cost-effectiveness of pediatric heart transplantation across a positive crossmatch for high waitlist urgency candidates.Cost satisfaction analysis: a novel patient-based approach for economic analysis of the utility of fixed prosthodontics.A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischemic stroke.Cost-effectiveness of a physician-nurse supplementary triage assessment team at an academic tertiary care emergency department.Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.Liver transplantation in a managed care environment.The importance of the measurement of ATP depletion and subsequent cell damage with an estimate of size and nature of the market for a practicable method: a review designed for technology transfer.Economic evaluation in health: a thumb nail sketch.Health economic evaluation.Charges and resource utilization for pediatric heart transplantation across a positive virtual and/or cytotoxicity crossmatch.Cost-of-Illness in Rare Diseases.Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach.Multiple tests of cost-effectiveness angles.
P2860
Q31995669-8BED1074-931E-4094-9CDB-DF90A25F2062Q33874659-42D253C0-665D-4391-9911-1E94B9E35E6DQ33886356-8295F23A-F2C7-4ADE-ADB9-7F63E9EF5FDEQ33916762-6F0577B8-4FF2-47F5-8ADB-877DD455F904Q34214204-0A1A0CA8-66D5-458A-888E-00DD3EA78608Q34219006-F3CC6424-3063-4AE0-B87D-5DA8EF7AD99BQ34219017-3D1546C7-E594-4DA3-B841-0C025D20B33DQ34219027-CE552DE0-2E27-4942-99F7-9A4F4E0EC29EQ34337037-2C566A31-3E73-4EBF-B2F9-248965ACB188Q34618578-5F2BF00A-3119-4F25-8CB9-FEA331A87541Q34907447-F368E7D6-D351-4334-9359-2C5CC9191E3AQ35107990-6F5A6C30-FDBA-4A5D-AF7E-D6C766F834EAQ35338286-E1BAD126-AA53-429A-912A-32C41279D36CQ35338427-667AC389-5875-4FC0-AD5C-2D1F5A576B3AQ35896010-AE5CEDD2-162D-4E91-A8A6-D0647B9D5225Q36098062-F170516A-A90D-4E57-A0A8-418509133FE4Q36234262-29A5DC14-9523-450D-B127-10186F9C58EBQ36266814-F8FD7066-6C65-4FD1-8FBB-1E3F853B195AQ36580694-F2D769EE-19D3-4020-8186-59BEB498D457Q36926231-B30E20F4-4410-405E-9B2D-DA20104D1C70Q38014110-C4C2762C-1E95-4302-9046-BF16034BB926Q38665544-5DEE323D-E580-4DAF-9B76-4DCB64CA2EF5Q40577333-D3B125F2-70C5-4C9F-B462-E7497C082055Q40873936-2AD56364-1127-420E-AD3F-9120F5C24DFAQ41622895-27B9E8A9-1E9E-49D7-9AA6-A0C0A94EAC9AQ41698159-216229E0-21CA-4D15-85B9-8D8750D8E741Q41772484-29E53C12-EC85-4B70-9547-D1ED92E8734FQ43079751-88E9F174-294C-4C76-B93C-81B34A206C6EQ47293101-0BB33151-3847-4020-973D-3B044D2F395FQ47353417-C8CE95FC-89B7-4753-8DDA-5F67A7F8B251Q48041192-8F1D8642-BE1F-41E2-A25F-8C118B8AA2D7Q51340958-8CB42BAA-703E-4690-AF81-735F490E85BB
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Cost-effectiveness analysis
@ast
Cost-effectiveness analysis
@en
type
label
Cost-effectiveness analysis
@ast
Cost-effectiveness analysis
@en
prefLabel
Cost-effectiveness analysis
@ast
Cost-effectiveness analysis
@en
P2860
P356
P1433
P1476
Cost-effectiveness analysis
@en
P2093
Robinson R
P2860
P304
P356
10.1136/BMJ.307.6907.793
P407
P577
1993-09-01T00:00:00Z